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However, the procedure was complicated by thrombus
propagation to the left and right common carotid arteries,
which resulted in a transient ischemic attack. Intravenous
abciximab (Reopro, Centocor, Malvern, Pa), a potent
platelet surface-membrane glycoprotein IIb/IIIa receptor
antagonist, was administered immediately, and it dissolved
the thrombus and reversed the neurologic symptoms.
CASE REPORT
A 67-year-old man had a 2-day history of shortness of breath
and hemoptysis. His medical history was significant for congestive
heart failure, hypertension, and diabetes mellitus. The patient
underwent a three-vessel CABG procedure 1 year earlier, which
was complicated by postoperative sternal osteomyelitis of methi-
cillin-resistant Staphylococcus aureus and Pseudomonas aurogenosa
and severe mediastinitis. During a subsequent 6-month course of
intravenous antibiotic treatment, he also underwent multiple rad-
ical debridement of the sternum followed by sternal resection,
and a bilateral pectoral muscle flap reconstruction was performed
5 months after the CABG. On examination, he was cachectic and
in mild distress. He was tachypneic with severe expiratory inter-
costal retraction. A bronchoscopy was performed, by means of
which an area of hemorrhagic mucosa was identified in the right
lateral bronchus without active bleeding. However, an area of
extrinsic compression was noted in the right main bronchus.
Although methicillin-resistant S aureus was revealed by means of
bronchial washing, no bacterial growth was shown by means of
blood culture results. A mycotic pseudoaneurysm in the ascend-
ing aorta, measuring 3 × 5 cm2 (Fig 1), was demonstrated by
means of a computed tomography scan of the chest, and the
pseudoaneurysm and multiple mediastinal nodules were con-
firmed by means of a magnetic resonance image of the chest. No
evidence of carcinoma was demonstrated by means of a medi-
Although several recent reports have documented the
efficacy of percutaneous thrombin injection in inducing
thrombosis of groin pseudoaneurysms,1,2 the feasibility of
thrombin injection as a means of treating a pseudoan-
eurysm in the mediastinum, such as an ascending aortic
pseudoaneurysm, remains unknown. The conventional
treatment of choice for an aortic pseudoaneurysm is oper-
ative repair with either primary closure or interposition
graft. More recently, the use of a stent-graft to exclude
aortic pseudoaneurysm has been embraced as an effective
treatment in high-risk patients who otherwise could not
tolerate an operative procedure.3,4 However, when an aor-
tic pseudoaneurysm occurs because of infection, treatment
with either an interposition graft or stent-graft exclusion
poses a therapeutic dilemma because of the potential graft
infection.
In this report, we describe the case of a patient in
whom an ascending aortic pseudoaneurysm developed
because of mediastinitis and sternal osteomyelitis after
coronary artery bypass grafting (CABG). An intra-arterial
injection of thrombin, which successfully induced throm-
bosis of the aortic pseudoaneurysm, was performed.
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CASE REPORTS
Intra-arterial thrombin injection of an ascending
aortic pseudoaneurysm complicated by transient
ischemic attack and rescued with systemic
abciximab
Peter H. Lin, MD,a Ruth L. Bush, MD,a Frank C. Tong, MD,b Elliot Chaikof, MD, PhD,a Louis G.
Martin, MD,b and Alan B. Lumsden, MD,a Atlanta, Ga
Thrombin injection as a means of inducing thrombus formation has recently received wide attention as an alternative
treatment for pseudoaneurysm. We present a case of a 67-year-old man in whom a large mycotic pseudoaneurysm devel-
oped in the ascending aorta because of sternal osteomyelitis and mediastinitis after coronary artery bypass grafting.
Transcatheter intra-arterial thrombin injection was performed, and it successfully induced pseudoaneurysm thrombo-
sis. However, the procedure was complicated by a sudden transient ischemic attack caused by thrombus propagation
into the cerebral circulation. Complete thrombus dissolution in the cerebral circulation with the resolution of neuro-
logic symptoms was achieved by means of intravenous abciximab. (J Vasc Surg 2001;34:939-42.)
astinoscopy with biopsy of the nodules, but inflammatory tissues
that grew methicillin-resistant S aureus were found. A mycotic
pseudoaneurysm of the ascending aorta compressing the right
main bronchus, caused in part by the patient’s recent sternal
osteomyelitis and mediastinitis, was diagnosed. A forced expira-
tory volume of 0.5 L in 1 second was revealed by means of a pul-
monary function test.
Given the patient’s multiple medical comorbidities, we
deemed him to be at high-risk for undergoing an operative repair
of the aortic pseudoaneurysm. An intra-arterial injection of
thrombin was given as a means of inducing thrombosis of the
pseudoaneurysm. After the insertion of a 9F introducer sheath
(Meditech/Boston Scientific Vascular, Oakland, NJ) in the right
groin, an arch aortogram was performed, by means of which a
pseudoaneurysm in the ascending aorta with a wide neck of 2 cm
was demonstrated (Fig 2). Patent bilateral carotid and vertebral
arteries were also noted on the initial aortogram. With a 0.035-in
Bentson guidewire (Meditech) placed within the pseudoan-
eurysm, a 6 Forgarty embolectomy catheter (Meditech) was
inserted over the guidewire through an 8F guiding catheter
(Meditech) and positioned within the pseudoaneurysm cavity.
The distal balloon of the embolectomy catheter was slightly over-
inflated and gently withdrawn to seal the pseudoaneurysm neck
(Fig 3). After the removal of the guidewire, 3 mL of iodinated
contrast was injected through the guidewire lumen of the
embolectomy catheter to ensure that the flow within the
pseudoaneurysm had been arrested by the embolectomy balloon
occlusion of the neck. As a means of inducing pseudoaneurysm
thrombosis, 2 mL of sterile normal saline containing 2000 units
of thrombin (1000 U/mL, Gentrac, Middletown, Wis) was
infused into the pseudoaneurysm through the guidewire lumen of
the embolectomy catheter in 20 seconds. Then the embolectomy
balloon was deflated, and the catheter was slowly removed from
the pseudoaneurysm. At this point, the patient suddenly experi-
enced left facial weakness with right hemiplegia that lasted
approximately 30 seconds. The same neurologic symptoms
recurred 10 minutes later, but remained persistent. A thrombosed
aortic pseudoaneurysm and intraluminal thrombus in the innom-
inate artery and left and right common carotid arteries were
demonstrated by means of a thoracic arch angiogram (Fig 4).
In an attempt to rescue and dissolve the intraluminal throm-
bus, we gave the patient an intravenous bolus of 0.25 mg/kg
abciximab, followed by a maintenance infusion of 10 µg/min for
12 hours. His neurologic symptoms resolved 20 minutes after the
abciximab infusion. Thirty minutes later, complete resolution of
the thrombus in the common carotid arteries without evidence of
distal embolism in the cerebral circulation was shown by means of
a second aortogram. The patient continued to receive the abcix-
imab infusion overnight in the intensive care unit. He remained
free of neurologic and respiratory symptoms and was discharged
3 days later, taking a daily dose of 75 mg oral clopidogrel (Plavix,
Bristol-Meyers, New York, NY) for 1 month. In follow-up visits
4 and 8 months later, a thrombosed aortic pseudoaneurysm, 2.3
× 4.4 cm2 and without evidence of aneurysm perfusion, was
demonstrated by means of computed tomography scans of the
chest, and the patient remained free of any neurologic and respi-
ratory symptoms.
DISCUSSION
We describe a case in which a mycotic pseudo-
aneurysm of the ascending aorta occurred because of
sternal osteomyelitis and mediastinitis after CABG.
Conventional therapy for an aortic pseudoaneurysm is
operative resection with either a patch aortotomy or inter-
position graft placement. In high-risk patients who could
not tolerate an operative procedure, placement of a stent-
graft device to exclude the pseudoaneurysm has become
an attractive alternative, with several recent reports docu-
menting the technical feasibility and excellent short-term
follow-up results.3,4 In our patient, who had shortness of
breath because of the large mycotic pseudoaneurysm with
compression of the right main bronchus, the treatment
objective was to exclude the pseudoaneurysm from the
aortic circulation without performing an open chest oper-
ation or placing a prosthetic graft because of his frail con-
dition and the potential risk of foreign-body infection. We
recently reported our experience with an endovascular
approach for treating carotid pseudoaneurysm, which
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Fig 1. Computed tomography scan of chest demonstrating a 3 ×
5-cm2 mycotic pseudoaneurysm in ascending aorta (arrow).
Fig 2. Arch aortogram demonstrating pseudoaneurysm in
ascending aorta with wide neck.
consisted of intraluminal carotid stent insertion for coil
trapping followed by detachable coil placement within the
pseudoaneurysm cavity to induce thrombosis.5 However,
such an approach was not feasible in this patient for sev-
eral reasons. First, the large cavity of the pseudoaneurysm
would require an enormous number of coils, making it
difficult to induce stable thrombus within the pseudo-
aneurysm. Second, the presence of a large number of coils
and an aortic stent could potentially lead to foreign-body
infection. Finally, the aortic stent might be insufficient to
trap coils within the large pseudoaneurysm neck that was
in our patient, which could potentially lead to coils escap-
ing into the aortic circulation and causing systemic
atheroembolism.
The feasibility of inducing pseudoaneurysm thrombo-
sis with percutaneous thrombin injection with ultrasound
scanning guidance has been demonstrated by means of
recent studies.1,2 Such a treatment approach is ideal in the
case of groin pseudoaneurysms, in which a superficially
located cavity is amenable to percutaneous thrombin
injection. Furthermore, a superficial groin pseudoan-
eurysm can be easily examined with ultrasound scanning
for neck compression, which may prevent inadvertent
thrombin propagation into the lower-extremity circula-
tion. In our patient, who had an ascending aortic
pseudoaneurysm, the percutaneous thrombin injection
could be hazardous because the rib cage would prevent an
adequate compression of the pseudoaneurysm neck by the
ultrasound scanning probe during thrombin injection.
Consequently, we chose to administer thrombin by means
of a catheter-guided intra-arterial injection directly into
the pseudoaneurysm cavity. To prevent thrombin from
escaping into the arch aorta, we placed an over-the-wire
embolectomy catheter in the pseudoaneurysm cavity that
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occluded the neck with the distal balloon inflation, while
the thrombin solution was slowly infused through the
guidewire lumen of the embolectomy catheter. We postu-
lated that the temporary exclusion of the pseudoaneurysm
neck by an embolectomy balloon would further halt the
arterial flow within the pseudoaneurysm cavity and, there-
fore, potentiate the thrombus formation.
When the thrombin injection was completed, the
embolectomy balloon was deflated, and the catheter was
withdrawn from the pseudoaneurysm. Immediately there-
after, a transient ischemic attack, manifested by left facial
weakness and right hemiplegia, developed in the patient.
With a documented presence of acute thrombus in the
innominate and carotid circulation, two possible mecha-
nisms could have accounted for such an occurrence. First,
a small amount of residual thrombin within the catheter
may have escaped and entered the cerebral circulation as
the catheter was removed from the aortic arch. Second,
the deflation of the embolectomy balloon may have
caused fresh thrombus to escape from the pseudo-
aneurysm, resulting in cerebral embolism.
With the presence of acute thrombus in the carotid
arteries, we chose to administer abciximab immediately as
a rescue attempt to dissolve the thrombus. Because acute
thrombus is known to be platelet rich, abciximab was cho-
sen because of its potent platelet receptor blockade prop-
erty that prevents platelet cross-linking and aggregation.6
After 30 minutes of abciximab infusion, dissolution of the
thrombus was demonstrated by means of a second aor-
togram. Possible mechanisms that could account for its
thrombolytic effects include active platelet deaggregation
at the thrombus site, endogenous autothrombolysis, and
inhibition of platelet-rich thrombus propagation.6
Fig 3. A 6 Fogarty embolectomy catheter was used for pseudoan-
eurysm neck occlusion (arrow) while thrombin solution was
infused through guidewire lumen. Fig 4. Thoracic arch angiogram demonstrating thrombosed
pseudoaneurysm; intraluminal thrombus was noted in the innom-
inate artery (arrow).
The efficacy of abciximab has been studied quite exten-
sively in the cardiology literature, with a predominant role
of reducing the thrombotic complications after coronary
intervention. When given in conjunction with either coro-
nary angioplasty or stenting, it appears to reduce both
platelet aggregation and fibrin deposition in the coronary
vasculature.7,8 Its “rescue” role in dissolving coronary
artery thrombosis that occurs after coronary angioplasty,
stent placement, or both has been highlighted in several
recent reports.9-11 When used with heparin and aspirin, it
has been found to potentiate thrombus dissolution in
patients with acute myocardial infarction.10 The use of
abciximab in dissolving thrombus in the cerebral circula-
tion was recently reported in a patient in whom carotid
artery occlusion developed because of acute carotid stent
thrombosis. Immediate infusion of systemic abciximab
resulted in complete dissolution of the acute carotid
thrombosis in 20 minutes.12 Its usefulness in cerebral
thrombolysis was similarly illustrated in a patient in whom
a basilar artery thrombosis developed after transluminal
angioplasty. After repeated efforts of thrombolysis with
urokinase and heparin, which were unsuccessful in recanal-
izing the thrombosed basilar artery, catheter-directed
abciximab infusion completely dissolved the intraluminal
thrombus and prevented rethrombosis.13 Lempert et al14
recently reported on a patient in whom acute parent vessel
thrombosis developed during Guglielmi detachable coil
placement for intracranial aneurysm embolization; intra-
venous systemic abciximab successfully dissolved the intra-
luminal thrombus. In our patient, systemic infusion of
abciximab may have successfully dissolved the thrombus in
the carotid circulation. As a result, his facial weakness and
contralateral hemiplegia resolved after the dissolution of
the intraluminal thrombus.
In summary, our case underscored the therapeutic chal-
lenges of a mycotic aortic pseudoaneurysm in a patient who
was deemed to be at high-risk for undergoing operative
repair. Because the placement of a prosthetic graft or stent-
graft device could potentially lead to foreign-body infection,
we chose to infuse thrombin intra-arterially as a means of
inducing pseudoaneurysm thrombosis. Although we antici-
pated the potential pitfalls of intra-arterial thrombin injec-
tion, which included possible thrombus propagation into
the aortic circulation, an embolectomy catheter was used as
a means of temporarily occluding the pseudoaneurysm neck.
Despite this maneuver, a transient ischemic attack developed
because of bilateral carotid thrombus propagation. The
propagated thrombus and neurologic symptoms of our
patient were successfully rescued with a potent platelet sur-
face-membrane glycoprotein IIb/IIIA receptor, abciximab.
As a result, we were fortunate in our patient’s outcome. In
retrospect, intra-arterial injection of thrombin of the ascend-
ing aortic pseudoaneurysm of a wide neck base was a 
hazardous maneuver, partly because of the thrombus
embolization to the cerebral circulation. Given the compli-
cation encountered in our patient, we do not recommend it
as a treatment option in patients with a wide-neck aortic
pseudoaneurysm.
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